Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
IL-5 antagonist
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2016
gptkb:FDA |
| gptkbp:brand |
gptkb:Cinqair
|
| gptkbp:class |
biologic therapy
|
| gptkbp:clinical_trial |
Phase III
eosinophilic asthma |
| gptkbp:contraindication |
hypersensitivity to reslizumab
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:frequency |
every 4 weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
reslizumab
|
| gptkbp:ingredients |
gptkb:reslizumab
|
| gptkbp:is_monitored_by |
eosinophil counts
|
| gptkbp:is_used_for |
gptkb:asthma
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Teva_Pharmaceuticals
|
| gptkbp:pharmacokinetics |
long half-life
|
| gptkbp:side_effect |
headache
muscle spasms oropharyngeal pain |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:interleukin-5
|
| gptkbp:bfsParent |
gptkb:interleukin-5
|
| gptkbp:bfsLayer |
5
|